1240518-75-5

Upstream product

• 94088-46-7 2-fluoro-6-methoxybenzonitrile 
• 1240518-08-4 5-chloro-N-[4-(methyloxy)-1H-indazol-3-yl]-N-({[2-(trimethylsilyl)ethyl]oxy}methyl)-2-thiophenesulfonamide 
• 509073-67-0 3-(bromomethyl)benzamide 
• 1240518-07-3 1,1-dimethylethyl 3-[[(5-chloro-2-thienyl)sulfonyl]({[2-(trimethylsilyl)ethyl]oxy}methyl)amino]-4-(methyloxy)-1H-indazole-1-carboxylate 
• 1240518-06-2 1,1-dimethylethyl 3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazole-1-carboxylate 
• 1240518-05-1 1,1-dimethylethyl 3-amino-4-(methyloxy)-1H-indazole-1-carboxylate 
• 886362-07-8 4-(methyloxy)-1H-indazol-3-amine 
• 135654-16-9 3-(chloromethyl)benzamide 

Downstream Products

• 1240516-78-2 3-{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1-yl]methyl}benzamide 

Relevant academic research and scientific papers

Lead optimisation of the N1 substituent of a novel series of indazole arylsulfonamides as CCR4 antagonists and identification of a candidate for clinical investigation

Synthesis and preliminary SAR of the N1 substituent of a novel series of indazole sulfonamide chemokine receptor 4 (CCR4) antagonist is reported. Compound 7r was identified for further development.

NOVEL COMPOUNDS

Indazole compounds, processes for their preparation, intermediates usable in these processes, pharmaceutical compositions containing such compounds and their use in therapy.